After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. | After promising to sell off 7% of its business back in November, Charles River Laboratories ...

Charles River Laboratories agreed to sell certain drug discovery assets to IQVIA for about $145 million and to divest its contract development and manufacturing and cell solutions businesses to GI ...

Charles River Labs divests European Discovery assets to IQVIA and CDMO/Cell Solutions to GI Partners; 2026 guidance updated.

Charles River Laboratories CRL on Wednesday announced significant plans to divest parts of its business. Charles River agreed to divest its CDMO and Cell Solutions businesses, along with certain ...

The expanded offerings will allow IQVIA to serve a broader range of drug modalities and therapeutic areas.

Lab services company Charles River Laboratories (NYSE:CRL) reported in Q4 CY2025, but sales were flat year on year at $994.2 ...

Feb 25 (Reuters) - Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and ...

What Happened? A number of stocks fell in the morning session after the Trump administration's announcement of new global ...

In a company press release, Charles River said Glenn G. Coleman will become Corporate Executive Vice President and Chief Financial Officer on April 6, taking charge of the firm’s global finance ...

It may be cold enough for ice on the Charles River in Boston, but emergency officials say not to be fooled into going onto it.

Business: Charles River Laboratories is an early-stage contract research company. The company engages in laboratory animal medicine and science (research model technologies), and it has developed a ...